An Open Label, Prospective, Multicentric Study to Evaluate the Safety and Efficacy of BIOMAb-EGFRTM (Nimotuzumab) As Induction and Maintenance Therapy in Combination with Radiotherapy plus Temozolomide (Concomitant and Adjuvant) In Indian Patients with Glioblastoma Multiforme

Trial Profile

An Open Label, Prospective, Multicentric Study to Evaluate the Safety and Efficacy of BIOMAb-EGFRTM (Nimotuzumab) As Induction and Maintenance Therapy in Combination with Radiotherapy plus Temozolomide (Concomitant and Adjuvant) In Indian Patients with Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Biocon
  • Most Recent Events

    • 15 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top